semaglutide after kidney transplant in patients with failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study - Vanek - 2024 - Diabetes, Obesity and Metabolism Glp-1 receptor agonists: A boon

6 MedStar Georgetown University Hospital, Washington, D.C., USA The Journal of Headache and Pain 2026 , 27(S1): P053 Objective Evaluate the impact of atogepant (Ato) on frequency and pain severity of moderate to severe monthly migraine headache days (MHDs), categorised by Patients Global Impression of Change (PGIC) response

People with existing kidney disease should be especially careful

In fat cells , it promotes improved fat metabolism and reduces inflammation All mechanisms are supported by the 2025 narrative review in Biomedicines, which highlights GLP-1s multifaceted role in satiety, insulin regulation, glycogen production, and fat metabolism GLP1 Medications Are Gaining Popularity

Hypoglycemia During Therapy of Diabetes